Bitcoin price today: dips to $92k as Fed cut doubts spark risk-off mood
Investing.com -- Novo Nordisk has started selling its weight-loss drug Wegovy for $349 a month to cash payers, implementing the price cut months earlier than planned under its agreement with the Trump administration.
The Danish drugmaker announced Monday that the same cash price will apply to most doses of its diabetes drug Ozempic, except for the highest 2 mg dose, which will remain at $499.
This move comes after Novo Nordisk and U.S. President Donald Trump announced a deal earlier this month to reduce the prices of both medications from $499 to $350 monthly for cash payers starting in January.
U.S. competitor Eli Lilly also plans to offer its lowest dose obesity medicine Zepbound for $299 monthly beginning in January, with additional doses priced at $449 for cash-paying patients under the same deal.
Novo Nordisk described Monday’s price reduction as part of a broader initiative to expand access to "authentic, FDA-approved semaglutide medicines."
The company also introduced a promotional offer of $199 monthly for the lowest two doses of Wegovy and Ozempic. This deal is available for two months to new cash-paying patients who start treatment between now and March 31, 2026.
Customers can access these new cash offers through the Ozempic or Wegovy websites, Novo’s NovoCare site, or partners including GoodRx, WeightWatchers and Costco.
GoodRx announced it will launch a weight-loss telehealth service for Wegovy and Ozempic priced at $39 monthly for subscribers who register before February 1, 2026, increasing to $119 monthly afterward.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.